Comparative Claims In Product Promotions: FDA Isn’t Entirely Leaving It To Firms To ‘Duke It Out’
Executive Summary
Four years after Woodcock’s famous comments, OPDP notes it is evaluating comparative claims as indicated in a recent untitled letter. DOJ is also looking at comparative claims. New FDA guidances are in the works, but it remains unknown when they will issue.
You may also be interested in...
Novartis’ Kisqali Consumer Promos Inappropriately Convey Superiority, NAD Finds In Unusual Ruling
However, similar claim in materials directed at health care providers need not be discontinued, National Advertising Division says in challenge brought by Lilly; NAD decisions in Rx promotion disputes are rare, but voluntary resolution process could become more appealing to pharma firms.
US FDA Mulls Granting Regulated Industry Flexibility To Respond To Misinformation
The rapid pace with which inaccurate information can spread on social media may necessitate loosening some of FDA’s regulations on sponsors to let them respond, Commissioner Robert Califf said at the J.P. Morgan Healthcare Conference. Califf also worried about how legitimate debate can undermine public confidence in FDA.
US FDA Mulls Granting Regulated Industry Flexibility To Respond To Misinformation
The rapid pace inaccurate information spreads on social media may necessitate loosening some of FDA’s regulations to let sponsors respond, Commissioner Robert Califf said at J.P. Morgan Healthcare Conference. Califf also worried about how legitimate debate can undermine public confidence in FDA.